<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564954</url>
  </required_header>
  <id_info>
    <org_study_id>CRIT124EUS19</org_study_id>
    <nct_id>NCT00564954</nct_id>
  </id_info>
  <brief_title>A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo
      during an 8-hour laboratory classroom day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn &amp; Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day</measure>
    <time_frame>0 hr and 0.5 hr post-dose</time_frame>
    <description>SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)</measure>
    <time_frame>0, 1, 2, 4, 6, and 8 hr</time_frame>
    <description>SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, and 8 hours</time_frame>
    <description>SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose in SKAMP Deportment Score</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6 and 8 hours</time_frame>
    <description>SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test-Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6 and 8 hours</time_frame>
    <description>Number of math questions attempted within a 10 minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6 and 8 hours</time_frame>
    <description>Number of math questions answered correctly within a 10 minute period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Dex-methylphenidate hydrochloride (Focalin XR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg capsule orally once a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>orally once a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dex-methylphenidate hydrochloride extended-release (Focalin XR)</intervention_name>
    <description>20 mg capsule orally once a day for 7 days</description>
    <arm_group_label>Dex-methylphenidate hydrochloride (Focalin XR)</arm_group_label>
    <other_name>Focalin XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally once a day for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 6-12 years, inclusive.

          -  Subjects meeting the DSM-IV criteria for ADHD of any type, as established by the
             K-SADS-PL (Kiddie Schedule for Affective Disorders and Schizophrenia-Present and
             Lifetime Version). If a DSM-IV-defined ADHD diagnosis is difficult to establish due to
             possible co-morbidity, the subject will not be enrolled into the study.

          -  Subjects should be on a stabilized total daily dose or nearest equivalent of 40-60 mg
             methylphenidate or 20-30 mg of d-methylphenidate for at least two weeks prior to
             screening visit (Concerta® 36 mg and 54 mg is allowable)

        Exclusion Criteria:

          -  Parent or guardian unable or unwilling to complete the Conner's ADHD/DSM-IV Scale for
             Parents (CADS-P) and the Daily Diary Card

          -  Diagnosed with a tic disorder or Tourette's syndrome

          -  History of seizure disorder

          -  The presence of a known medical condition that would preclude the use of
             methylphenidate. A history (within the past year) or presence of clinically
             significant cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal,
             pulmonary, immunological, hematological, endocrine, or neurological disease

          -  ALT, AST, GGPT or serum creatinine greater then 2X the ULN at Screening

          -  A history of psychiatric illness or substance use disorder (e.g., schizophrenia,
             bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or
             severe Oppositional defiant disorder)

          -  Subjects who have participated in an investigational trial within the past 4 weeks (28
             days) are excluded

          -  Subjects who are currently taking antidepressants or other psychotropic medication

          -  Subjects who have initiated psychotherapy during the three months prior to
             randomization

          -  Subjects with a positive urine drug screen

          -  Subjects who have a history of poor response or intolerance to methylphenidate or
             d-methylphenidate

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2007</study_first_submitted>
  <study_first_submitted_qc>November 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <results_first_submitted>November 25, 2008</results_first_submitted>
  <results_first_submitted_qc>February 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2009</results_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>children</keyword>
  <keyword>laboratory classroom</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dex-methylphenidate Hydrochloride (Focalin XR) Then Placebo</title>
          <description>Period 1: One 20 mg capsule of Focalin XR taken once daily in the morning for one week followed by Period 2: one week of placebo taken once daily in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Dex-methylphenidate Hydrochloride (Focalin XR)</title>
          <description>Period 1: One week of placebo taken once daily in the morning followed by Period 2: one week of one 20 mg capsule of Focalin XR taken once daily in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1- 1 Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2- 1 Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dex-methylphenidate Hydrochloride (Focalin XR) Then Placebo</title>
          <description>Period 1: One 20 mg capsule of Focalin XR taken once daily in the morning for one week followed by Period 2: one week of placebo taken once daily in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Dex-methylphenidate Hydrochloride (Focalin XR)</title>
          <description>Period 1: One week of placebo taken once daily in the morning followed by Period 2: one week of one 20 mg capsule of Focalin XR taken once daily in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="2.0"/>
                    <measurement group_id="B2" value="9.4" spread="1.4"/>
                    <measurement group_id="B3" value="9.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)</title>
        <description>SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.</description>
        <time_frame>0, 1, 2, 4, 6, and 8 hr</time_frame>
        <population>Intent to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
            <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)</title>
          <description>SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.</description>
          <population>Intent to Treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.358" spread="0.993"/>
                    <measurement group_id="O2" value="5.670" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.573" spread="0.856"/>
                    <measurement group_id="O2" value="5.467" spread="0.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.395" spread="0.847"/>
                    <measurement group_id="O2" value="3.925" spread="0.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.622" spread="0.950"/>
                    <measurement group_id="O2" value="5.346" spread="0.952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.260" spread="0.988"/>
                    <measurement group_id="O2" value="3.621" spread="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)</title>
        <description>SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.</description>
        <time_frame>0, 0.5, 1, 2, 4, 6, and 8 hours</time_frame>
        <population>Intent to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
            <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)</title>
          <description>SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.</description>
          <population>Intent to Treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.825" spread="0.524"/>
                    <measurement group_id="O2" value="0.862" spread="0.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.208" spread="0.589"/>
                    <measurement group_id="O2" value="2.304" spread="0.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.591" spread="0.507"/>
                    <measurement group_id="O2" value="2.465" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.722" spread="0.506"/>
                    <measurement group_id="O2" value="1.183" spread="0.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.819" spread="0.582"/>
                    <measurement group_id="O2" value="2.715" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.061" spread="0.584"/>
                    <measurement group_id="O2" value="1.415" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose in SKAMP Deportment Score</title>
        <description>SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.</description>
        <time_frame>0, 0.5, 1, 2, 4, 6 and 8 hours</time_frame>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
            <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose in SKAMP Deportment Score</title>
          <description>SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.</description>
          <population>Intent to Treat (ITT) population.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="0.550"/>
                    <measurement group_id="O2" value="2.226" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.863" spread="0.564"/>
                    <measurement group_id="O2" value="3.103" spread="0.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.850" spread="0.499"/>
                    <measurement group_id="O2" value="2.881" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.420" spread="0.526"/>
                    <measurement group_id="O2" value="2.511" spread="0.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.614" spread="0.541"/>
                    <measurement group_id="O2" value="2.393" spread="0.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.939" spread="0.560"/>
                    <measurement group_id="O2" value="1.969" spread="0.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test–Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)</title>
        <description>Number of math questions attempted within a 10 minute period.</description>
        <time_frame>0, 0.5, 1, 2, 4, 6 and 8 hours</time_frame>
        <population>Intent to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
            <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test–Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)</title>
          <description>Number of math questions attempted within a 10 minute period.</description>
          <population>Intent to Treat (ITT) population</population>
          <units>questions attempted</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="2.96"/>
                    <measurement group_id="O2" value="-4.74" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.26" spread="3.66"/>
                    <measurement group_id="O2" value="-12.18" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.52" spread="3.61"/>
                    <measurement group_id="O2" value="-10.19" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.01" spread="3.60"/>
                    <measurement group_id="O2" value="-7.42" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.33" spread="3.82"/>
                    <measurement group_id="O2" value="-16.70" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.04" spread="3.50"/>
                    <measurement group_id="O2" value="-10.08" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test</title>
        <description>Number of math questions answered correctly within a 10 minute period.</description>
        <time_frame>0, 0.5, 1, 2, 4, 6 and 8 hours</time_frame>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
            <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test</title>
          <description>Number of math questions answered correctly within a 10 minute period.</description>
          <population>Intent to Treat (ITT) population.</population>
          <units>questions correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="2.72"/>
                    <measurement group_id="O2" value="-5.96" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.10" spread="3.34"/>
                    <measurement group_id="O2" value="-13.21" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.92" spread="3.44"/>
                    <measurement group_id="O2" value="-11.09" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.64" spread="3.37"/>
                    <measurement group_id="O2" value="-7.52" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" spread="3.55"/>
                    <measurement group_id="O2" value="-16.90" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.37" spread="3.40"/>
                    <measurement group_id="O2" value="-11.44" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn &amp; Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day</title>
        <description>SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.</description>
        <time_frame>0 hr and 0.5 hr post-dose</time_frame>
        <population>Intent to Treat (ITT) population: All randomized patients who had at least one dose of study medication and who had at least one post-dose efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
            <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn &amp; Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day</title>
          <description>SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.</description>
          <population>Intent to Treat (ITT) population: All randomized patients who had at least one dose of study medication and who had at least one post-dose efficacy measurement.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.969" spread="0.909"/>
                    <measurement group_id="O2" value="3.336" spread="0.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dex-methylphenidate Hydrochloride (Focalin XR)</title>
          <description>Summary of the one week treatment on dex-methylphenidate hydrochloride (Focalin XR), 20 mg capsule orally once a day, for all 86 patients regardless of sequence.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Summary of the one week treatment on placebo once a day orally for 7 days for all 86 patients regardless of sequence.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary; however, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

